-DOCSTART- -X- O
INTRODUCTION -X- _ O
: -X- _ O
Middle -X- _ B-Patient
East -X- _ I-Patient
Respiratory -X- _ I-Patient
Coronavirus -X- _ I-Patient
Virus -X- _ I-Patient
( -X- _ I-Patient
MERS-CoV -X- _ I-Patient
) -X- _ I-Patient
first -X- _ O
emerged -X- _ O
from -X- _ O
Saudi -X- _ O
Arabia -X- _ O
in -X- _ O
2012 -X- _ O
and -X- _ O
has -X- _ O
since -X- _ O
been -X- _ O
recognized -X- _ O
as -X- _ O
a -X- _ O
significant -X- _ O
human -X- _ O
respiratory -X- _ O
pathogen -X- _ O
on -X- _ O
a -X- _ O
global -X- _ O
level. -X- _ O
METHODS -X- _ O
: -X- _ O
In -X- _ O
this -X- _ O
narrative -X- _ O
review -X- _ O
, -X- _ O
we -X- _ O
focus -X- _ O
on -X- _ O
the -X- _ O
prevention -X- _ O
of -X- _ O
MERS-CoV. -X- _ B-Patient
We -X- _ O
searched -X- _ O
PubMed -X- _ O
, -X- _ O
Embase -X- _ O
, -X- _ O
Cochrane -X- _ O
, -X- _ O
Scopus -X- _ O
, -X- _ O
and -X- _ O
Google -X- _ O
Scholar -X- _ O
, -X- _ O
using -X- _ O
the -X- _ O
following -X- _ O
terms -X- _ O
: -X- _ O
‘MERS’ -X- _ B-Patient
, -X- _ I-Patient
‘MERS-CoV’ -X- _ I-Patient
, -X- _ I-Patient
‘Middle -X- _ I-Patient
East -X- _ I-Patient
respiratory -X- _ I-Patient
syndrome’ -X- _ I-Patient
in -X- _ O
combination -X- _ O
with -X- _ O
‘prevention’ -X- _ B-Intervention
or -X- _ I-Intervention
‘infection -X- _ I-Intervention
control’. -X- _ I-Intervention
We -X- _ O
also -X- _ O
reviewed -X- _ O
the -X- _ O
references -X- _ O
of -X- _ O
each -X- _ O
article -X- _ O
to -X- _ O
further -X- _ O
include -X- _ O
other -X- _ O
studies -X- _ O
or -X- _ O
reports -X- _ O
not -X- _ O
identified -X- _ O
by -X- _ O
the -X- _ O
search. -X- _ O
RESULTS -X- _ O
: -X- _ O
As -X- _ B-Outcome
of -X- _ I-Outcome
Nov -X- _ I-Outcome
2019 -X- _ I-Outcome
, -X- _ I-Outcome
a -X- _ I-Outcome
total -X- _ I-Outcome
of -X- _ I-Outcome
2468 -X- _ I-Outcome
laboratory-confirmed -X- _ I-Outcome
cases -X- _ I-Outcome
of -X- _ I-Outcome
MERS-CoV -X- _ I-Outcome
were -X- _ I-Outcome
diagnosed -X- _ I-Outcome
mostly -X- _ I-Outcome
from -X- _ I-Outcome
Middle -X- _ I-Outcome
Eastern -X- _ I-Outcome
regions -X- _ I-Outcome
with -X- _ I-Outcome
a -X- _ I-Outcome
mortality -X- _ I-Outcome
rate -X- _ I-Outcome
of -X- _ I-Outcome
at -X- _ I-Outcome
least -X- _ I-Outcome
35 -X- _ I-Outcome
% -X- _ I-Outcome
. -X- _ I-Outcome
A -X- _ I-Outcome
major -X- _ I-Outcome
outbreak -X- _ I-Outcome
that -X- _ I-Outcome
occurred -X- _ I-Outcome
outside -X- _ I-Outcome
the -X- _ I-Outcome
Middle -X- _ I-Outcome
East -X- _ I-Outcome
( -X- _ I-Outcome
in -X- _ I-Outcome
South -X- _ I-Outcome
Korea -X- _ I-Outcome
) -X- _ I-Outcome
and -X- _ I-Outcome
infections -X- _ I-Outcome
reported -X- _ I-Outcome
from -X- _ I-Outcome
27 -X- _ I-Outcome
countries. -X- _ I-Outcome
MERS-CoV -X- _ I-Outcome
has -X- _ I-Outcome
gained -X- _ I-Outcome
recognition -X- _ I-Outcome
as -X- _ I-Outcome
a -X- _ I-Outcome
pathogen -X- _ I-Outcome
of -X- _ I-Outcome
global -X- _ I-Outcome
significance. -X- _ I-Outcome
Prevention -X- _ I-Outcome
of -X- _ I-Outcome
MERS-CoV -X- _ I-Outcome
infection -X- _ I-Outcome
is -X- _ I-Outcome
a -X- _ I-Outcome
global -X- _ I-Outcome
public -X- _ I-Outcome
health -X- _ I-Outcome
priority. -X- _ I-Outcome
Healthcare -X- _ I-Outcome
facility -X- _ I-Outcome
transmission -X- _ I-Outcome
and -X- _ I-Outcome
by -X- _ I-Outcome
extension -X- _ I-Outcome
community -X- _ I-Outcome
transmission -X- _ I-Outcome
, -X- _ I-Outcome
the -X- _ I-Outcome
main -X- _ I-Outcome
amplifier -X- _ I-Outcome
of -X- _ I-Outcome
persistent -X- _ I-Outcome
outbreaks -X- _ I-Outcome
, -X- _ I-Outcome
can -X- _ I-Outcome
be -X- _ I-Outcome
prevented -X- _ I-Outcome
through -X- _ I-Outcome
early -X- _ I-Outcome
identification -X- _ I-Outcome
and -X- _ I-Outcome
isolation -X- _ I-Outcome
of -X- _ I-Outcome
infected -X- _ I-Outcome
humans. -X- _ I-Outcome
While -X- _ I-Outcome
MERS-CoV -X- _ I-Outcome
vaccine -X- _ I-Outcome
studies -X- _ I-Outcome
were -X- _ I-Outcome
initially -X- _ I-Outcome
hindered -X- _ I-Outcome
by -X- _ I-Outcome
multiple -X- _ I-Outcome
challenges -X- _ I-Outcome
, -X- _ I-Outcome
recent -X- _ I-Outcome
vaccine -X- _ I-Outcome
development -X- _ I-Outcome
for -X- _ I-Outcome
MERS-CoV -X- _ I-Outcome
is -X- _ I-Outcome
showing -X- _ I-Outcome
promise. -X- _ I-Outcome
CONCLUSIONS -X- _ O
: -X- _ O
The -X- _ O
main -X- _ O
factors -X- _ O
leading -X- _ O
to -X- _ O
sustainability -X- _ O
of -X- _ O
MERS-CoV -X- _ O
infection -X- _ O
in -X- _ O
high -X- _ O
risk -X- _ O
courtiers -X- _ O
is -X- _ O
healthcare -X- _ O
facility -X- _ O
transmission. -X- _ O
MERS-CoV -X- _ O
transmission -X- _ O
in -X- _ O
healthcare -X- _ O
facility -X- _ O
mainly -X- _ O
results -X- _ O
from -X- _ O
laps -X- _ O
in -X- _ O
infection -X- _ O
control -X- _ O
measures -X- _ O
and -X- _ O
late -X- _ O
isolation -X- _ O
of -X- _ O
suspected -X- _ O
cases. -X- _ O
Preventive -X- _ O
measures -X- _ O
for -X- _ O
MERS-CoV -X- _ O
include -X- _ O
disease -X- _ O
control -X- _ O
in -X- _ O
camels -X- _ O
, -X- _ O
prevention -X- _ O
of -X- _ O
camel -X- _ O
to -X- _ O
human -X- _ O
transmission -X- _ O
. -X- _ O

